Table 2.

Outcome after post–allo-HCT nivolumab administration

PatientTransplantation modalities and complicationsNivolumabOutcome
Donor typeConditioningHistory of GVHD/typeLocalizationGradeTime from allo-HCT to initiation (mo)Treatment duration (weeks)Reason for discontinuationNivolumab-induced GVHDFollow-up (d)*Current statusCause of death
LocalizationTreatmentGrade
1 MUD Thio-Bu-Flu Acute/chronic Skin/ mucosa, mild II 15 2 Nivolumab-induced GVHD Liver Corticosteroids and cyclosporine III 154 Still in response NA 
2 Double unit-CB Flu-Cy-TBI Acute Skin and gastrointestinal tract III 9 2 Nivolumab-induced GVHD Skin Corticosteroids I 223 Still in response NA 
3 MRD Flu-Bu-ATG Acute Skin III 19 2 Nivolumab-induced GVHD Liver Corticosteroids III 105 Died in response Grade III GVHD and care refusal 
4 MRD Flu-Bu-ATG Acute Skin and gastrointestinal tract II 8 2 Nivolumab-induced GVHD Skin Corticosteroids III 363 Still in response NA 
5 MUD Flu-TBI-ATG Acute Skin II 2 2 Nivolumab-induced GVHD Skin and liver No immunosuppressive therapy IV NE Response not evaluable Multiple organ failure 
6 Haplo (father) Flu-Cy-TBI Acute Skin and gastrointestinal tract III 7 2 Nivolumab-induced GVHD Skin Corticosteroid, basiliximab and photopheresis IV 132 Death after relapse Progressive disease 
7 MRD Flu-Bu-ATG Acute Skin II 17 50 Ongoing No   188 Relapse, new response after re-treatment NA 
8 MUD Flu-Bu-ATG Acute Skin III 51 33 Relapse No   245 Relapse NA 
9 MRD Flu-Bu-ATG Acute Skin and gastrointestinal tract II 27 34 Ongoing No   231 Still in response NA 
10 MRD Flu-Mel Acute Skin I 59 67 Ongoing No   450 Still in response NA 
11 Double-unit CB Flu-Cy-TBI Chronic Skin NA 29 13 Consolidation with a second allo-HCT No   468 Still in response NA 
12 MRD Flu-TBI Chronic Mucosa NA 105 67 Ongoing No   462 Still in response NA 
13 MMUD Flu-Bu-ATG Chronic Skin NA 7 7 Cerebellar ataxia No   437 Still in response NA 
14 MMUD Flu-TBI No   28 17 Relapse No   117 Relapse NA 
15 MRD Flu-Bu-ATG No   12 14 Relapse No   98 Relapse Complications of second allo-HCT 
16 MRD Flu-Bu-ATG No   27 55 Ongoing No   365 Still in response NA 
17 Double-unit CB Flu-Cy-ATG No   12 55 Ongoing No   374 Still in response NA 
18 MMUD Flu-Bu-ATG No   33 21 Hematologic toxicity No   456 Still in response NA 
19 MRD Flu-Bu-ATG No   111 71 Ongoing No   486 Still in response NA 
20 MRC Flu-Bu-ATG No   53 8 No response No   56 No response NA 
PatientTransplantation modalities and complicationsNivolumabOutcome
Donor typeConditioningHistory of GVHD/typeLocalizationGradeTime from allo-HCT to initiation (mo)Treatment duration (weeks)Reason for discontinuationNivolumab-induced GVHDFollow-up (d)*Current statusCause of death
LocalizationTreatmentGrade
1 MUD Thio-Bu-Flu Acute/chronic Skin/ mucosa, mild II 15 2 Nivolumab-induced GVHD Liver Corticosteroids and cyclosporine III 154 Still in response NA 
2 Double unit-CB Flu-Cy-TBI Acute Skin and gastrointestinal tract III 9 2 Nivolumab-induced GVHD Skin Corticosteroids I 223 Still in response NA 
3 MRD Flu-Bu-ATG Acute Skin III 19 2 Nivolumab-induced GVHD Liver Corticosteroids III 105 Died in response Grade III GVHD and care refusal 
4 MRD Flu-Bu-ATG Acute Skin and gastrointestinal tract II 8 2 Nivolumab-induced GVHD Skin Corticosteroids III 363 Still in response NA 
5 MUD Flu-TBI-ATG Acute Skin II 2 2 Nivolumab-induced GVHD Skin and liver No immunosuppressive therapy IV NE Response not evaluable Multiple organ failure 
6 Haplo (father) Flu-Cy-TBI Acute Skin and gastrointestinal tract III 7 2 Nivolumab-induced GVHD Skin Corticosteroid, basiliximab and photopheresis IV 132 Death after relapse Progressive disease 
7 MRD Flu-Bu-ATG Acute Skin II 17 50 Ongoing No   188 Relapse, new response after re-treatment NA 
8 MUD Flu-Bu-ATG Acute Skin III 51 33 Relapse No   245 Relapse NA 
9 MRD Flu-Bu-ATG Acute Skin and gastrointestinal tract II 27 34 Ongoing No   231 Still in response NA 
10 MRD Flu-Mel Acute Skin I 59 67 Ongoing No   450 Still in response NA 
11 Double-unit CB Flu-Cy-TBI Chronic Skin NA 29 13 Consolidation with a second allo-HCT No   468 Still in response NA 
12 MRD Flu-TBI Chronic Mucosa NA 105 67 Ongoing No   462 Still in response NA 
13 MMUD Flu-Bu-ATG Chronic Skin NA 7 7 Cerebellar ataxia No   437 Still in response NA 
14 MMUD Flu-TBI No   28 17 Relapse No   117 Relapse NA 
15 MRD Flu-Bu-ATG No   12 14 Relapse No   98 Relapse Complications of second allo-HCT 
16 MRD Flu-Bu-ATG No   27 55 Ongoing No   365 Still in response NA 
17 Double-unit CB Flu-Cy-ATG No   12 55 Ongoing No   374 Still in response NA 
18 MMUD Flu-Bu-ATG No   33 21 Hematologic toxicity No   456 Still in response NA 
19 MRD Flu-Bu-ATG No   111 71 Ongoing No   486 Still in response NA 
20 MRC Flu-Bu-ATG No   53 8 No response No   56 No response NA 

ATG, antithymocyte globulin; Bu, busulfan; CB, cord blood; Cy, cyclophosphamide; Flu, fludarabine; Haplo, familial haploidentical donor; Mel, melphalan; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; NA, not applicable; TBI, total body irradiation; Thio, thiotepa.

*

Follow-up duration is given from nivolumab initiation.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal